ClinicalTrials.gg
WithdrawnNCT05702788COVID-19Updated Apr 26, 2024

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

A Phase 2 interventional study of Jaktinib hydrochloride tablets and Jaktinib hydrochloride tablets in COVID-19 and Pneumonia, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor R\&D Strategy Adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.

02

Conditions studied

  • COVID-19
  • Pneumonia
03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age, male or female;
  • The Participants was diagnosed with novel coronavirus pneumonia;
  • It meets the heavy-duty standards of the new coronavirus pneumonia diagnosis and treatment protocol (version 9).
  • Participants who voluntarily sign .
  • The National Institute of Allergy and Infectious Diseases Sequential Scale (NIAID-0S) score is 5 or 6;

Exclusion criteria

Exclusion Criteria:

  • Participants who cannot take orally, or are suspected to be allergic to Jaktinib, similar drugs or their , or have severe gastrointestinal dysfunction that affects drug absorption;
  • Participants who have received the following treatments within the specified time window before randomization:

    1. Participants have received Janus kinase (JAK) inhibitor, interleukin 6 (IL-6) inhibitor, IL-1 inhibitor, tumor necrosis factor (TNF) inhibitor, T cell or B cell depletion agent, interferon and other drugs within the first two weeks of randomization, except ;
    2. Systematically used CYP 3A4 potent inhibitor or potent inducer in the first five drug half lives at random;
  • Immune deficiency;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Jaktinib 75mg BID

    Jaktinib 75mg BID

    Drug: Jaktinib hydrochloride tablets

  • Experimental
    Jaktinib 100mg BID

    Jaktinib 100mg BID

    Drug: Jaktinib hydrochloride tablets

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • 75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.

  • 100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.

  • OtherPlacebo

    Placebo (given as two placebo tablets) administered orally BID with best available treatment.

06

What researchers measure

Primary outcomes

  1. The proportion of Participants who develop death or respiratory failure.

    Respiratory failure is defined as Participants who on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation(ECMO) or on non-invasive ventilation or high-flow oxygen devices.

    Time frame: 28 days after randomization

Secondary outcomes

  1. The proportion of Participants who develop death or respiratory failure.

    Respiratory failure is defined as Participants who on invasive mechanical ventilation or ECMO or on non-invasive ventilation or high-flow oxygen devices.

    Time frame: 14 days after randomization

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2023
First posted
Jan 27, 2023
StartEst.
Sep 2022
Primary completionActual
Apr 23, 2024
CompletionActual
Apr 23, 2024
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05702788
Responsible party
Sponsor
First posted
Jan 27, 2023
Start date
Sep 2022 (estimated)
Primary completion
Apr 23, 2024
Completion
Apr 23, 2024
Last update
Apr 26, 2024

Study contacts

Hongzhou Lu
principal investigator · The Third People Hospital of Shenzhen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion